CTI BioPharma: Rises after starting cancer drug marketing application submission

CTI Biopharma

13/10/2020 14:27

** Drug developer's  CTIC.O  shares rise 4.2% to $3.21
premarket
    ** CTIC starts rolling submission of marketing application
to the U.S FDA for its experimental treatment, pacritinib, for a
type of bone marrow cancer  urn:newsml:reuters.com:*:nPn7zBHzha
    ** A rolling submission allows a drug company to submit
sections of its marketing application to the FDA for review,
instead of completing every section before submitting the
application
    ** CTIC says it is planning for commercial launch of the
drug in 2021  
    ** Up to Monday's, close stock had gained 95% this year

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))